SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Weissleder R. Molecular imaging: exploring the next frontier. Radiology 1999; 212: 609614.
  • 2
    Wickline SA, Lanza GM. Molecular imaging, targeted therapeutics, and nanoscience. J Cell Biochem 2002; 39: 9097.
  • 3
    Gupta H, Weissleder R. Targeted contrast agents. Magn Reson Imaging Clin N Am 1996; 4: 171184.
  • 4
    Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002; 22: 539548.
  • 5
    Lanza GM, Abendschein DR, Hall CH, Marsh JN, Scott MJ, Scherrer DE, Wickline SA. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. Invest Radiol 2000; 35: 227234.
  • 6
    Lanza GM, Abendschein DR, Hall CH, Scott MJ, Scherrer DE, Houseman A, Miller JG, Wickline SA. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr 2000; 13: 608614.
  • 7
    Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Fuhrhop RJ, Scherer DE, Wickline SA. Targeted antiproliferative drug delivery to vascular smooth muscle cells with an MRI nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002; 106: 28422847.
  • 8
    Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Zhang H, Robertson DJ, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 Tesla MRI. Cancer Res 2003; 63: 58385858.
  • 9
    Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with aνb3-integrin-targeted nanoparticles. Circulation 2003; 108: 22702274.
  • 10
    Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, Mclean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001; 104: 12801285.
  • 11
    Yu X, Song S-K, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000; 44: 867872.
  • 12
    Winter PM, Caruthers SD, Yu X, Song S-K, Fuhrhop RW, Scott MJ, Chen J, Miller B, Bulte JWM, Gaffney PJ, Wickline SA, Lanza GM. Improved molecular imaging contrast agent for early detection of unstable atherosclerotic plaques. Magn Reson Med 2003; 50: 411416.
  • 13
    Landsberger S. Delayed instrumental neutron activation analysis. In: AlfassiZB, editor. Chemical analysis by nuclear methods. New York: John Wiley & Sons; 1994. p 122140.
  • 14
    Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Prolonged inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96: 646652.
  • 15
    St. Pierre J, Yang L-Y, Tamirisa K, Scherrer D, Deciechi P, Eisenberg P, Tolunay E, Abendschein D. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999; 19: 22632268.
  • 16
    In den Kleef JJ, Cuppen JJ. RLSQ: T1, T2, and rho calculations, combining ratios and least squares. Magn Reson Med 1987; 5: 513524.
  • 17
    Kirsch JE. Basic principles of magnetic resonance contrast agents. Top Magn Reson Imaging 1991; 3: 118.
  • 18
    Ahrens ET, Rothbacher U, Jacobs RE, Fraser SE. A model for MRI contrast enhancement using T1 agents. Proc Natl Acad Sci USA 1998; 5: 84438448.
  • 19
    Rose A. The sensitivity performance of the human eye on an absolute scale. J Opt Soc Am 1948; 38: 196208.
  • 20
    Button TM, Fiel RJ. Isointense model for the evaluation of tumor-specific MRI contrast agents. Magn Reson Imaging 1988; 6: 275280.
  • 21
    Unger EC, Totty WG, Neufeld DM, Otsuka FL, Murphy WA, Welch MS, Connett JM, Philpott GW. Magnetic resonance imaging using gadolinium labeled monoclonal antibody. Invest Radiol 1985; 20: 693700.
  • 22
    Shreve P, Aisen AM. Monoclonal antibodies labeled with polymeric paramagnetic ion chelates. Magn Reson Med 1986; 3: 336340.
  • 23
    Gillies RJ. In vivo molecular imaging. J Cell Biochem 2002; 39 (Suppl): 231238.
  • 24
    Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA. Magneto-dendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001; 19: 11411147.
  • 25
    Hendrick RE, Haacke EM. Basic physics of MR contrast agents and maximization of image contrast. J Magn Reson Imaging 1993; 3: 137148.
  • 26
    Ahrens ET, Rothbacher U, Jacobs RE, Fraser SE. A model for MRI contrast enhancement using T1 agents. Proc Natl Acad Sci USA 1998; 95: 84438448.
  • 27
    Hendrick RE, Nelson TR, Hendee WR. Optimizing tissue contrast in magnetic resonance imaging. Magn Reson Imaging 1984; 2: 193204.
  • 28
    Nelson TR, Hendrick RE, Hendee WR. Selection of pulse sequences producing maximum tissue contrast in magnetic resonance imaging. Magn Reson Imaging 1984; 2: 285294.
  • 29
    Perman WH, Hilal SK, Simon HE, Maudsley AA. Contrast manipulation in NMR imaging. Magn Reson Imaging 1984; 2: 2332.
  • 30
    Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 1970; 41: 250251.
  • 31
    Allport JR, Weissleder R. In vivo imaging of gene and cell therapies. Exp Hematol 2001; 29: 12371246.
  • 32
    Wickline SA, Lanza GM. Nanotechnology for molecular imaging and targeted therapy. Circulation 2003; 107: 10921095.